<DOC>
	<DOCNO>NCT01424319</DOCNO>
	<brief_summary>Prospective , randomize , double-blind , placebo control , 12-week , multicenter study . The objective study evaluate efficacy safety daily administration atrasentan tablet compare placebo reduce residual albuminuria Japanese Type 2 diabetic patient nephropathy treat maximum tolerated label dose hypertension RAS ( renin angiotensin system ) inhibitor .</brief_summary>
	<brief_title>Reducing Residual Albuminuria Subjects With Diabetes Nephropathy With Atrasentan</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Patient Type 2 diabetes treat least one antihyperglycemic medication within 12 month prior screen period . Patient receive maximum tolerate label dose ACEi ( Angiotensin Converting Enzyme inhibitor ) ARB ( Angiotensin II Receptor Blocker ) ( Renin Angiotensin System ( RAS ) inhibitor ) . Estimated GFR ( Glomerular Filtration Rate ) great equal 30 less equal 75 mL/min/1.73m2 CKD ( chronic kidney disease ) Epidemiology Collaboration ( EPI ) formula . UACR ( Urinary Albumin Creatinine Ratio ) great equal 200 mg/g determine geometric mean three morning void urine specimen obtain Runin period . Serum albumin great equal 3.0 g/dL . BNP ( Btype Natriuretic Peptide ) less equal 200 pg/mL . SBP ( Systolic Blood Pressure ) great equal 110 mmHg less equal 160 mmHg . HbA1c ( Glucosylated Hemoglobin A1c ) less equal 12 % serum potassium less equal 5.5 mEq/L . Patient history moderate severe edema , facial edema unrelated trauma , history myxedema prior 6 month screen . Patient receive loop diuretic great equal 120 mg QD ( Once Daily ) furosemide great equal 3.0 mg QD ( Once Daily ) bumetanide great equal 150 mg QD ( Once Daily ) ethacrynic acid great equal 60 mg QD ( Once Daily ) torasemide . Patient documented history Stage C Stage D heart failure , define ACC/AHA ( American College Cardiology/ American Heart Association Practice Guidelines ) . Patient receive combination ACEi ( Angiotensin Converting Enzyme inhibitor ) ARB ( Angiotensin II Receptor Blocker ) rosiglitazone aliskiren aldosterone antagonist patient receive pioglitazone edema present .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Endothelin Receptor Antagonists</keyword>
	<keyword>Proteinuria</keyword>
</DOC>